Delisting risk
BioAtla
Developer of pH-sensitive CAB oncology biologics.
$1.76
After-hours close−0.01 (−0.56%)
At close$1.77(−43.63%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$7.00 | — | — |
| Aug 2026 | −$8.50 | $0.27 | +103.2% |
| May 2026 | −$10.00 | −$6.18 | +38.2% |
| Mar 2026 | −$12.00 | −$8.00 | +33.3% |
| Nov 2025 | −$0.31 | −$0.27 | +12.9% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$7.00 | — | — | $5.6M | — | — |
| Aug 13, 2026 | −$8.50 | $0.27 | +103.2% | $6.5M | $6.5M | 0.0% |
| May 15, 2026 | −$10.00 | −$6.18 | +38.2% | — | — | — |
| Mar 31, 2026 | −$12.00 | −$8.00 | +33.3% | $700.0K | $2.0M | +185.7% |
| Nov 13, 2025 | −$0.31 | −$0.27 | +12.9% | — | — | — |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 6, 2025 | ||||||
| Mar 27, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 14, 2024 | ||||||
| Mar 26, 2024 | ||||||
| Nov 7, 2023 | ||||||
| Aug 1, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 23, 2023 | ||||||
| Nov 4, 2022 | ||||||
| Aug 9, 2022 | ||||||
| May 5, 2022 | ||||||
| Mar 1, 2022 | ||||||
| Nov 15, 2021 | ||||||
| Aug 13, 2021 | ||||||
| May 12, 2021 | ||||||
| Mar 25, 2021 | ||||||
| Dec 17, 2020 | ||||||
| Mar 31, 2020 | ||||||
| Dec 31, 2019 | ||||||